v3.25.4
Significant Accounting Policies - Net Loss per Member Unit (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Significant Accounting Policies                    
Net loss $ (1,823,351) $ 113,287 $ (327,526) $ (601,372) $ (961,207) $ (1,753,978) $ (2,037,590) $ (3,316,557)    
Basic weighted average units outstanding (in shares) [1] 27,007,568     17,500,000     22,637,742 17,500,000    
Diluted weighted average units outstanding (in shares) 27,007,568     17,500,000     22,637,742 17,500,000    
Basic net loss per share [1] $ (0.07)     $ (0.03)     $ (0.09) $ (0.19)    
Diluted net loss per share $ (0.07)     $ (0.03)     $ (0.09) $ (0.19)    
Liminatus Pharma, LLC                    
Significant Accounting Policies                    
Net loss                 $ (3,546,000) $ (4,984,000)
Class A | Liminatus Pharma, LLC                    
Significant Accounting Policies                    
Percentage of earning and losses allocated to member units                 49.00%  
Net loss                 $ (1,738,000) $ (2,442,000)
Basic weighted average units outstanding (in shares)                 95,555,554 85,825,570
Diluted weighted average units outstanding (in shares)                 95,555,554 85,825,570
Basic net loss per share                 $ (0.02) $ (0.03)
Diluted net loss per share                 $ (0.02) $ (0.03)
Class B | Liminatus Pharma, LLC                    
Significant Accounting Policies                    
Percentage of earning and losses allocated to member units                 51.00%  
Net loss                 $ (1,808,000) $ (2,542,000)
Basic weighted average units outstanding (in shares)                 16,666,666 16,666,666
Diluted weighted average units outstanding (in shares)                 16,666,666 16,666,666
Basic net loss per share                 $ (0.11) $ (0.15)
Diluted net loss per share                 $ (0.11) $ (0.15)
[1] Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.